Xeris Biopharma Holdings, Inc. XERS Total debt
Total debt at other companies
Other financials
Where this comes from
Calculated from Xeris Biopharma Holdings, Inc.’s reported figures.
Plus components not separately reported this period.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s total debt?
- Xeris Biopharma Holdings, Inc. (XERS) reported total debt of $258.55M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s total debt changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s total debt decreased by 3.8% year-over-year, from $268.75M to $258.55M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s total debt?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s total debt has grown at a 24.3% compound annual growth rate (CAGR), from $87.02M to $258.1M.
- What does total debt mean?
- Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.